Global healthcare stocks have not been this cheap in decades and fund inflows into the sector are picking up, yet the shares remain in the doldrums, highlighting uncertainty over drug pricing policies ...

The pharmaceutical industry has a fresh sense of direction after President Donald Trump’s tax-and-spending law included a provision that could keep certain rare disease drugs from being subject to ...

Alnylam (ALNY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Real Chemistry’s latest acquisition adds up to Greater Than One. | Greater Than One will retain its name and New York City headquarters as it moves under the Real Chemistry umbrella, and its employees ...

The Invesco Biotechnology & Genome ETF (PBE) was launched on 06/23/2005, and is a smart beta exchange traded fund designed to offer broad exposure to the Health Care ETFs category of the market. What ...

Fintel reports that on July 21, 2025, Truist Securities initiated coverage of Alnylam Pharmaceuticals (NasdaqGS:ALNY) with a Buy recommendation. Analyst Price Forecast Suggests 6.19% Upside As of July ...

While most investors chase yesterday's headlines, Tim Melvin spots tomorrow's winners. See the exact system that found NVIDIA ...

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, ...

Alnylam Pharmaceuticals’ Amvuttra (vutrisiran) has been approved by the Medicines and Healthcare products Regulatory Agency ...

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he ...

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the second quarter ending June 30, 2025 on Thursday, July ...